Global Cancer Immunotherapy Market to Reach US$ 261.0 Billion by 2032, Propelled by Increasing Prevalence of Cancer

June 01, 2022 | Healthcare

The latest report by IMARC Group, titled “Cancer Immunotherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2032,” finds that the global cancer immunotherapy market size reached US$ 118.9 Billion in 2023. Cancer immunotherapy, also known as immuno-oncology, refers to biological therapy used to treat cancer. It works by altering or enhancing the immune system, enabling it to detect and destroy abnormal cells to prevent and curb the growth of various types of cancer. It uses substances produced by the body or synthesized in a laboratory to help the body fight cancer. It is more precise, effective, and personalized and has fewer side effects than traditional therapies. It can be used in combination with radiation, chemotherapy, surgery, or targeted therapies to enhance their effectiveness and prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. As a result, cancer immunotherapy is widely used across hospitals, cancer research centers, and clinics to control and eliminate different cancers.

Global Cancer Immunotherapy Market Trends:

The increasing prevalence of cancer and the escalating demand for advanced cancer therapeutics represent the primary factors driving the market growth. In addition, there has been a significant shift from traditional chemotherapy toward cancer immunotherapy due to the growing awareness regarding its efficacy and fewer side effects. Besides this, the surging incidences of multiple myeloma and melanoma have augmented the demand for cancer immunotherapy. Moreover, the rising government and private investments in research and development (R&D) activities in the cancer immunotherapy field have propelled the market growth. Furthermore, the leading players are developing novel immunotherapy variants with enhanced treatment efficacy and effectiveness. In line with this, the launch of several pharmaceutical company-sponsored patient assistance programs (PAPs) that provide financial support to low-income individuals to augment prescription drug coverage has positively influenced the market growth. Other factors, including the expanding healthcare industry, rising adoption of monoclonal antibodies (mAbs), supportive government initiatives, increasing regulatory approvals for new cancer immunotherapy drugs, and technological advancements in clinical therapies, are also creating a favorable market outlook. Looking forward, the market value is anticipated to reach US$ 261.0 Billion by 2032, growing at a CAGR of 8.92% during the forecast period (2024-2032).

Market Summary:

Based on the therapy type, the market has been divided into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, immunomodulators, and others.
On the basis of the application, the market has been segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others.
The market has been classified based on the end user into hospitals, cancer research centers, clinics, and others.
Region-wise, the market has been segregated into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
The competitive landscape of the market has also been analyzed, with some of the key players being Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A, Seagen Inc.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Segment Coverage	Therapy Type, Application, End User, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A and Seagen Inc.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas: - +1 631 791 1145 | Africa and Europe: - +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Cancer Immunotherapy Market to Reach US$ 261.0 Billion by 2032, Propelled by Increasing Prevalence of Cancer

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.